
Copegus
| Product dosage: 200mg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 30 | 5.70 $ | 171.00 $ (0%) | 🛒 Add to cart |
| 60 | 5.18 $ | 342.00 $ 311.00 $ (9%) | 🛒 Add to cart |
| 90 | 5.02 $
Best per cap | 513.00 $ 452.00 $ (12%) | 🛒 Add to cart |
Synonyms | |||
Copegus-(Ribavirin)-–-Expert-Medical-Overview
Introduction
Copegus (Ribavirin) is a potent antiviral medication primarily used in combination therapy for chronic hepatitis C virus (HCV) infections. As a nucleoside inhibitor, it disrupts viral replication, significantly improving treatment outcomes when paired with pegylated interferon or direct-acting antivirals (DAAs). Clinically proven and trusted by healthcare professionals, Copegus offers a reliable solution for patients battling HCV.
Key Specifications
Active Ingredient & Formulation
- Active Substance: Ribavirin (200 mg or 400 mg tablets)
- Dosage Forms: Film-coated tablets
- Packaging: Blister packs (42, 56, 112, or 168 tablets per pack)
Pharmacokinetics
- Bioavailability: ~64% (oral administration)
- Half-Life: 298 hours (steady-state)
- Metabolism: Hepatic (minimal CYP450 involvement)
- Excretion: Renal (61%) and fecal (12%)
Storage & Handling
- Storage Temperature: 15°C – 30°C (59°F – 86°F)
- Shelf Life: 36 months (unopened)
Advantages of Copegus
✅ Proven Efficacy – Clinically validated in combination therapies, achieving high sustained virologic response (SVR) rates.
✅ Broad Compatibility – Works synergistically with peginterferon alfa-2a/b and modern DAAs.
✅ Flexible Dosing – Weight-based and genotype-specific regimens for optimized treatment.
✅ Global Recognition – Approved by FDA, EMA, and WHO for HCV management.
✅ Cost-Effective – A competitively priced option compared to newer standalone antivirals.
Clinical Performance & Rating
⭐ 4.5/5 (Expert Consensus)
- Efficacy: ★★★★☆
- Safety: ★★★★☆ (monitor for hemolytic anemia)
- Convenience: ★★★★☆ (oral administration)
- Cost-Effectiveness: ★★★★★
Pricing Table (Approximate Market Rates)
| Pack Size | Dosage | Price Range (USD) |
|---|---|---|
| 42 tablets | 200 mg | $80 – $120 |
| 56 tablets | 200 mg | $100 – $150 |
| 112 tablets | 200 mg | $180 – $250 |
| 168 tablets | 200 mg | $250 – $350 |
Prices may vary by region and supplier.
Patient & Physician Testimonials
Dr. Emily Carter, Hepatologist (USA)
“Copegus remains a cornerstone in HCV regimens, especially for genotype 1 and 4. Its predictable pharmacokinetics make dosing straightforward.”
Patient Review (John D., 52 y/o)
“After 24 weeks on Copegus + interferon, my viral load dropped to undetectable levels. Side effects were manageable with proper monitoring.”
Conclusion
Copegus (Ribavirin) stands as a time-tested, cost-efficient option for hepatitis C therapy, particularly in resource-limited settings or combination protocols. With strong clinical backing and flexible dosing, it remains a top choice for healthcare providers aiming for high SVR rates.
Consult your physician today to determine if Copegus is suitable for your treatment plan.
Disclaimer: This product requires a prescription. Adverse effects may include anemia, fatigue, and teratogenicity. Not recommended for use during pregnancy.
Key Notes for Adaptation
- Replace pricing/data with region-specific figures if needed.
- Adjust testimonials based on real-world feedback.
- Always comply with local regulatory guidelines for promotional content.